Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease

You'll see more nonalcoholic fatty liver disease (NAFLD).

Up to 100 million Americans have this buildup of fat in the liver. It often goes hand in hand with obesity, dyslipidemia, insulin resistance, and diabetes.

About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH)...the more severe form with inflammation and sometimes fibrosis. It's set to be the top reason for liver transplants in the U.S. by 2020.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals